IMD-0354

IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].

Product Specifications

CAS Number

[978-62-1]

Product Name Alternative

IKK2 Inhibitor V

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IKK

Type

Reference compound

Related Pathways

NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/IMD-0354.html

Purity

99.46

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC(Cl)=CC=C2O

Molecular Formula

C15H8ClF6NO2

Molecular Weight

383.67

Precautions

H302, H315, H319, H335

References & Citations

[1]Tanaka A, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005 Mar 15;105 (6) :2324-31.|[2]Li YR, et al. Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs. Chem Biol Drug Des. 2017 Dec;90 (6) :1307-1311.|[3]Tanaka A, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006 Jan 1;66 (1) :419-26.|[4]Lennikov A, et al. Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Mol Vis. 2012;18:2586-97.